Fracture Risk in Patients with Myasthenia Gravis: A Population-Based Cohort Study

Abstract

BACKGROUND: Prednisone is a common treatment for myasthenia gravis (MG), and osteoporosis is a known potential risk of chronic prednisone therapy. OBJECTIVE: Our aim was to evaluate the risk of serious fractures in a population-based cohort of MG patients.

Authors

Kassardjian C; Widdifield J; Paterson JM; Kopp A; Nagamuthu C; Barnett C; Tu K; Breiner A

Journal

Journal of Neuromuscular Diseases, Vol. 8, No. 4, pp. 625–632

Publisher

SAGE Publications

Publication Date

July 30, 2021

DOI

10.3233/jnd-200612

ISSN

2214-3599

Associated Experts

J Michael Paterson

Assistant Professor (Part-Time), Faculty of Health Sciences

Visit profile

Labels